Novavax Covax Agreement

Novavax Inc. has entered into an agreement with the COVAX initiative to supply its COVID-19 vaccine candidate, NVX-CoV2373, to low- and middle-income countries.

COVAX is a global initiative co-led by Gavi, the Vaccine Alliance, the World Health Organization (WHO), and the Coalition for Epidemic Preparedness Innovations (CEPI). Its aim is to ensure that all countries have access to COVID-19 vaccines, regardless of their income level.

Under the terms of the agreement, Novavax will supply up to 1.1 billion doses of its vaccine to COVAX, contingent upon regulatory approvals. The company will also provide technology transfer and technical assistance to support the transfer of manufacturing capabilities to COVAX`s network of vaccine manufacturers.

NVX-CoV2373 is a protein-based vaccine that has demonstrated strong efficacy in clinical trials. In a phase 3 trial conducted in the UK, the vaccine showed an overall efficacy of 96.4% against COVID-19, including the Alpha and Beta variants, and 100% efficacy against severe disease.

This agreement marks a significant step forward for COVAX in its efforts to provide equitable access to COVID-19 vaccines. To date, the initiative has shipped over 80 million doses to 129 countries, but more support is needed to reach its target of delivering 2 billion doses by the end of 2021.

“Novavax remains committed to bringing our COVID-19 vaccine to people around the world, especially those in low- and middle-income countries,” said Stanley C. Erck, President and Chief Executive Officer of Novavax. “This agreement with COVAX is a key part of that commitment, and we look forward to working with our partners to help end this pandemic.”

In conclusion, the Novavax-COVAX agreement is a positive development in the global fight against COVID-19. By ensuring that low- and middle-income countries have access to a highly effective vaccine, we can work towards ending the pandemic and returning to a sense of normalcy.